Immuneering (IMRX) Equity Ratio (2020 - 2024)
Immuneering (IMRX) has 5 years of Equity Ratio data on record, last reported at 0.84 in Q3 2024.
- For Q3 2024, Equity Ratio fell 7.82% year-over-year to 0.84; the TTM value through Sep 2024 reached 0.84, down 7.82%, while the annual FY2023 figure was 0.88, 1.65% down from the prior year.
- Equity Ratio reached 0.84 in Q3 2024 per IMRX's latest filing, down from 0.86 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.96 in Q3 2021 and bottomed at 0.66 in Q2 2021.
- Average Equity Ratio over 5 years is 0.7, with a median of 0.91 recorded in 2023.
- Peak YoY movement for Equity Ratio: soared 259.91% in 2021, then decreased 7.82% in 2024.
- A 5-year view of Equity Ratio shows it stood at 0.59 in 2020, then skyrocketed by 259.91% to 0.94 in 2021, then dropped by 4.06% to 0.9 in 2022, then dropped by 1.65% to 0.88 in 2023, then dropped by 4.64% to 0.84 in 2024.
- Per Business Quant database, its latest 3 readings for Equity Ratio were 0.84 in Q3 2024, 0.86 in Q2 2024, and 0.89 in Q1 2024.